Yuhan is preparing an Early Access Program (EAP) to provide free medication to patients until 슬롯 머신 becomes eligible for reimbursement
On June 30th, Yuhan Corporation, a leading pharmaceutical company in South Korea, gainedthe expansion of indications for 슬롯 머신 (active ingredient: Lazertinib) as a first-line treatment for non-small cell lung cancer with positive epidermal growth factor receptor (EGFR) mutations.
슬롯 머신 received approval in January 2021 for second-line treatment of locally advanced or metastatic non-small cell lung cancer with T790M mutation after 1~2G TKI failure.
According to the recent clinical Phase 3 trial LASER301, published in the JCO (Journal of Clinical Oncology), 슬롯 머신 demonstrated statistically significant improvement in progression-free survival (PFS) compared to the first-line treatment option, Iressa (active ingredient: gefitinib). Based on these results, a new drug application for first-line treatment was submitted in March.
JCOpublished by the American Society of Clinical Oncology (ASCO), is an esteemed international academic journal in the field of oncology, with an impressive “Impact Factor” of 50.739, reflecting its global recognition and influence.
Yeol-Hong Kim, the Chief Executive Officer of Research and Development (R&D) at Yuhan, expressed his delight, stating, “With this approval, we can now offer new treatment option for patients with non-small cell lung cancer who have a high prevalence of EGFR-positive mutations in South Korea.” He further added, “Having confirmed excellent efficacy and safety, we will be able to promptly offer high-quality pharmaceutical treatment opportunities to a greater number of patients as a first-line therapy.”
Meanwhile, Yuhan is preparing an application to expand the reimbursement criteria for 슬롯 머신 as a first-line treatment. This change in approval allows 슬롯 머신 to compete with other first-line therapies, including Tagrisso (active ingredient: Osimertinib), another third generation TKI.
Additionally, Yuhan is preparing an Early Access Program (EAP) as a humanitarian initiative to provide free medication to patients until 슬롯 머신 becomes eligible for reimbursement and prescription under the National Health Insurance (NHI). This program will be implemented from the approval date by each Institutional Review Board (IRB) until the expansion of reimbursement criteria for 슬롯 머신 takes effect.